Characterization of thalidomide using Raman spectroscopy

被引:13
作者
Cipriani, Penelope [1 ]
Smith, Candace Y. [1 ]
机构
[1] Spelman Coll, Dept Chem, Atlanta, GA 30314 USA
关键词
Raman; thalidomide; anticancer; frequency; DFT;
D O I
10.1016/j.saa.2007.04.002
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
Thalidomide is a potent anticancer therapeutic drug whose mechanism of action has not yet been elucidated. In this report, experimental Raman spectroscopy is used to determine and characterize the vibrational frequencies of the drug. These normal modes are then compared to their quantum mechanical counterparts, which have been computed using density functional theory. Upon analysis of the spectra, we found that there was a high level of agreement between the wavenumbers. As such, this spectroscopic technique may be a viable tool for examining the way in which this drug interacts with its target molecules. (C) 2007 Published by Elsevier B.V.
引用
收藏
页码:333 / 337
页数:5
相关论文
共 32 条
[1]  
BATTEGAY EJ, 1995, J MOL MED, V73, P333
[2]   Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].
Benjamin, LE ;
Keshet, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766
[3]   Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy [J].
Berry, W ;
Eisenberger, M .
ONCOLOGIST, 2005, 10 :30-39
[4]   THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[5]  
DARCY PF, 1994, ADVERSE DRUG REACT T, V13, P65
[6]   FITTING THE COULOMB POTENTIAL VARIATIONALLY IN X-ALPHA MOLECULAR CALCULATIONS [J].
DUNLAP, BI .
JOURNAL OF CHEMICAL PHYSICS, 1983, 78 (06) :3140-3142
[7]   Quantum chemical investigation of thalidomide molecule [J].
Erkoç, S ;
Erkoç, F .
JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 2005, 719 (1-3) :1-5
[8]   Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas [J].
Fine, HA ;
Figg, WD ;
Jaeckle, K ;
Wen, PY ;
Kyritsis, AP ;
Loeffler, JS ;
Levin, VA ;
Black, PM ;
Kaplan, R ;
Pluda, JM ;
Yung, WKA .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :708-715
[9]   TUMOR ANGIOGENESIS - POSSIBLE CONTROL POINT IN TUMOR-GROWTH [J].
FOLKMAN, J .
ANNALS OF INTERNAL MEDICINE, 1975, 82 (01) :96-100
[10]  
Foresman J., 2015, Exploring Chemistry with Electronic Structure Methods, V3rd